m+Medelevator.RU
← Поиск публикаций
Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2026

Artificial intelligence in diabetes care: Toward precision diagnosis and personalized management.

СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Aburjai Talal, Ali Agha Ahmed S A, Abuhilaleh Yara, Miqdad Anas, Aburjai Ahmad, Alzweiri Muhammed, El Khassawna Thaqif

Аннотация

Diabetes mellitus is a global health challenge requiring innovative solutions for early diagnosis, personalized treatment, and ongoing management. This review aims to examine the impact of artificial intelligence (AI) on diabetes care, focusing on precision diagnosis, tailored therapies, and real-time monitoring, while addressing challenges related to model transparency and equitable access to health care. We conducted a comprehensive review of AI applications in diabetes management. Studies utilizing supervised and unsupervised learning, deep learning, federated learning, and reinforcement learning were analyzed for predictive accuracy, clinical impact, and integration. Comparisons with conventional methods were also included. Machine learning models show strong predictive performance for diabetes risk assessment, with random forest algorithms reporting accuracy up to 97% in hospital-based datasets. Deep learning models applied to clinical cohorts have achieved approximately 94.6% accuracy in predicting adverse events in patients with type 2 diabetes. Reinforcement learning approaches for automated insulin delivery have maintained glucose within the normoglycemic range for up to 95.66% of simulated time in artificial pancreas studies. Federated learning enables privacy-preserving collaborative model development with performance comparable to centralized models. AI-driven decision-support systems and wearable technologies further support improved glycemic monitoring and patient self-management. However, model performance varies depending on dataset characteristics, patient populations, and evaluation protocols. AI has reshaped diabetes care by enabling precise diagnosis, individualized treatments, and adaptive disease management. Responsible implementation is essential to addressing ethical concerns and ensure equitable access. Future work should refine AI frameworks for broader clinical adoption, prioritizing patient-centered care and data security.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты